FindTrial
Sign In

A non-interventional, observational post-marketing registry of Vidaza (subcutaneous azacitidine) in patients with intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia with 20-30 % blasts and multi-lineage dysplasia in China

A non-interventional, observational post-marketing registry of Vidaza (subcutaneous azacitidine) in patients with intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia with 20-30 % blasts and multi-lineage dysplasia in China

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016423
Enrollment
Unknown
Registered
2018-06-01
Start date
2018-06-01
Completion date
Unknown
Last updated
2018-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia with 20-30 % blasts and multi-lineage dysplasia

Interventions

Case series:Vidaza

Sponsors

Tianjin Hematonosis Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Must understand and voluntarily sign an informed consent form (ICF) (Annex 1); 2. Patient who have already started or are to start treatment with Vidaza? in label.

Exclusion criteria

Exclusion criteria: 1. Patients who fail to provide signed ICF; 2. Patients with advanced malignant liver tumor; 3. Known to be allergic to azacitidine or mannitol.

Design outcomes

Primary

MeasureTime frame
AE;—

Countries

China

Contacts

Public ContactXiaolin Xia

Celgene Pharmaceutical (Shanghai) Co. Ltd

xxia@celgene.com+86 6062 6017

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026